ArticleBMC nephrology2025
Celastrol modulates damage of renal tissues in Immunoglobulin A nephropathy via targeting TGase-2/HMGB1 signaling pathway.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPersistent controversies surround the treatment of Immunoglobulin A nephropathy (IgAN), necessitating the exploration of safer and more effective therapeutic agents. Tripterygium wilfordii, a traditional Chinese medicine, demonstrates promising benefits in reducing proteinuria and enhancing renal function in IgAN. This study aims to elucidate the therapeutic mechanisms of celastrol, a principal medicinal component of Tripterygium wilfordii, in IgAN treatment.
methodsAn IgAN rat model was induced using lipopolysaccharide, carbon tetrachloride, and bovine serum albumin. HMCs cells were stimulated by aIgA1 to establish IgAN model in vitro. Immunofluorescence, immunohistochemistry and HE staining were performed using renal tissues. Western Blot and RT-PCR were utilized to measure the protein and mRNA expressions of TGase-2, HMGB1, TLR4, and MYD88 in vivo and in vitro.
resultsCelastrol treatment exhibited reduced levels of proteinuria, diminished pathological kidney damage, and decreased expression of TGase-2 and HMGB1 in the renal tissue of IgAN rats. Furthermore, celastrol treatment or TGase-2 knockdown decreased the expression of TGase-2, HMGB1, TLR4, and MYD88 in both proteins and mRNA levels in, and the contents of HMGB1, TNF-α, IL-6, and FN in the in aIgA1 stimulated HMCs.
conclusionOur study findings provide evidence supporting the efficacy of celastrol in treating IgAN. The potential underlying mechanisms involve the reduction of cell proliferation and inflammatory response by inhibiting the expression of the TGase-2/HMGB1 pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.